未经评估:我们旨在评估生活质量(QoL),疾病活动,遵守治疗,患者和医生对给药途径的偏好(RoA),开始晚期治疗或需要转换的RA患者的健康和疼痛状况,以及与患者偏好相关的因素。
未经批准:多中心,prospective,进行了观察性和1年随访研究,在2015年至2020年期间,首次使用高级治疗或需要转换当前治疗的成年RA患者。收集的所有数据都输入到电子病例报告表中。具有ESR[DAS28-4(ESR)]的28个接头中的DAS,EuroQol5维问卷(EQ-5D),HAQ残疾指数(HAQ-DI),风湿病学依从性问卷(CQR-19),使用工作效率和活动障碍量表(WPAI)和患者全球评估-视觉模拟量表(PGA-VAS)问卷进行纵向评估。
UNASSIGNED:纳入了四百五十九名患者。三百八位患者(67.1%)在12个月时参加了最终的研究访问,并被纳入比较分析。无论RoA,12个月时,疾病活动和QoL显著改善,而合规性恶化。在基线和12个月时,EQ-5D与DAS28-4(ESR)评分显著相关(P<0.001)。在开始晚期治疗或转换后的12个月内,WPAI评分显着变化,有利于更好的结果(P<0.001)。较高比例的患者更喜欢口服RoA,与医生相比(53.6%vs31.4%;P<0.001)。患者和医生的RoA偏好与性别无关,年龄,疾病持续时间,高级处理型和EQ-5D-3L,DAS28-4(ESR),HAQ-DI,基线时的PGA-VAS和CQR-19评分。
未经证实:与医生相比,患者更倾向于口服途径,尽管患者的偏好率在治疗结束时略有增加,这可能是RA结果的重要因素。在12个月时实现了对疾病活动和QoL的更好控制,不管RoA。
UNASSIGNED: We aimed to evaluate quality of life (QoL), disease activity, compliance to treatment, patient and physician preferences for route of administration (RoA), status of health and pain in RA patients starting advanced treatments or needing a switch, and the factors associated with patient preferences.
UNASSIGNED: A multicentre, prospective, observational and 1-year follow-up
study was conducted, between 2015 and 2020, in adult RA patients using advanced treatments for the first time or needing a switch in their current treatments. All the data collected were entered into electronic case report forms.
DAS in 28 joints with ESR [DAS28-4(ESR)], EuroQol 5-Dimensional Questionnaire (EQ-5D), HAQ Disability Index (HAQ-DI), Compliance Questionnaire for Rheumatology (CQR-19), Work Productivity and Activity Impairment Instrument (WPAI) and Patient Global Assessment-Visual Analogue Scale (PGA-VAS) questionnaires were used for longitudinal assessments.
UNASSIGNED: Four hundred and fifty-nine patients were enrolled. Three hundred and eight patients (67.1%) attended the final
study visit at 12 months and were included for comparative analyses. Irrespective of RoA, the disease activity and QoL improved significantly at 12 months, whereas compliance worsened. At baseline and 12 months, EQ-5D and DAS28-4(ESR) scores were significantly correlated (P < 0.001). The WPAI scores changed significantly in favour of better outcomes over 12 months after initiation of advanced treatment or switching (P < 0.001). A higher proportion of patients preferred an oral RoA, in comparison to physicians (53.6% vs 31.4%; P < 0.001). Patient and physician RoA preferences were independent of gender, age, disease duration, advanced treatment type and the EQ-5D-3L, DAS28-4(ESR), HAQ-DI, PGA-VAS and CQR-19 scores at baseline.
UNASSIGNED: The oral route was more frequently preferred by patients compared with physicians, although patients\' preference rates showed a slight increase towards the end of the treatment, which might be an important factor for RA outcomes. Better control of disease activity and QoL were achieved at 12 months, regardless of RoA.